Evaluation of Devices Used with Regenerative Medicine Advanced Therapies

Guidance for Industry

For questions on the content of this guidance, contact Center for Biologics Evaluation and Research (CBER), Office of Communication, Outreach, and Development (OCOD) at 800-835-4709 or 240-402-8010, or email ocod@fda.hhs.gov. For questions about this document concerning products regulated by Center for Devices and Radiological Health (CDRH), contact the Office of the Center Director at 301-796-5900. If you need additional assistance with regulation of combination products, contact the Office of Combination Products (OCP) at 301-796-8930.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Biologics Evaluation and Research
Center for Devices and Radiological Health
Office of Combination Products
February 2019
Evaluation of Devices Used with Regenerative Medicine Advanced Therapies

Guidance for Industry

Additional copies are available from:
Office of Communication, Outreach and Development
WO71, Room 3103
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993
Phone: 800-835-4709 or 240-402-8010
ocod@fda.hhs.gov


or

Office of the Center Director
Guidance and Policy Development
Center for Devices and Radiological Health
Food and Drug Administration
10903 New Hampshire Ave., WO66, Room 5431
Silver Spring, MD 20993
Phone: 301-796-5900


or

Office of Combination Products
Office of Special Medical Programs
Office of the Commissioner
Food and Drug Administration
10903 New Hampshire Ave., WO32, Hub 5129
Silver Spring, MD 20993
Phone: 301-796-8930
Fax: 301-847-8619
combination@fda.gov

https://www.fda.gov/CombinationProducts/default.htm
# Table of Contents

I. INTRODUCTION ............................................................................................................. 1  
II. SCOPE ........................................................................................................................... 2  
III. GENERAL APPROACH: DEVICE CLASSIFICATION AND STREAMLINING  
     OF APPLICATION OF REGULATORY REQUIREMENTS ........................................... 4  
IV. COMBINATION PRODUCTS .................................................................................... 9  
V. FACTORS TO CONSIDER FOR WHEN A DEVICE MAY BE INTENDED FOR  
   USE WITH ONLY ONE PARTICULAR TYPE OF CELL-BASED RMAT OR  
   WITH MORE THAN ONE TYPE OF CELL-BASED RMAT ....................................... 10
Evaluation of Devices Used with Regenerative Medicine Advanced Therapies

Guidance for Industry

This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff responsible for this guidance as listed on the title page.

I. INTRODUCTION

This guidance provides manufacturers, applicants, and sponsors engaged in the development of regenerative medicine therapies, with FDA’s current thinking regarding evaluation of devices used in the recovery, isolation, or delivery of regenerative medicine advanced therapies.

Section 3034 of the 21st Century Cures Act\(^1\) (Cures Act) mandates that FDA issue guidance clarifying how FDA will evaluate devices used in the recovery, isolation, or delivery of regenerative advanced therapies, as such term is used in section 506(g) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 356(g)) and which FDA generally refers to as “regenerative medicine advanced therapies” or “RMATs.” Accordingly, this guidance discusses what FDA will consider when evaluating the devices used with RMATs. This document includes information about the Agency’s current thinking regarding a wide range of concepts related to the regulation of devices, as they apply to devices used in the recovery, isolation, and delivery of RMATs. Specifically, this guidance addresses how FDA intends to simplify and streamline its application of regulatory requirements for combination device and cell or tissue products;\(^2\) what, if any, intended uses or specific attributes would result in a device used with a regenerative therapy product to be classified as a Class III device;\(^3\) the factors to consider in determining whether a device may be labeled for use with a specific RMAT or class of RMATs; when a device may be limited to a specific intended use with only one particular type of cell; and application of the least burdensome approach to demonstrate how a device may be used with more than one cell type.

\(^{1}\) Public Law 114-255.

\(^{2}\) For purposes of this guidance, the term “combination device and cell or tissue products” is not necessarily limited to “combination product” as defined under 21 CFR Part 3.

\(^{3}\) As explained in section III of this guidance, we are unable to provide a definitive list of intended uses or specific attributes that would result in a device used with an RMAT being classified as a Class III device, but have instead addressed this requirement of section 3034 of the Cures Act by providing information about characteristics of Class III devices.
Contains Nonbinding Recommendations

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities. Instead, guidances describe the FDA’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in FDA’s guidances means that something is suggested or recommended, but not required.

II. SCOPE

This guidance applies to medical devices used in the recovery, isolation, or delivery of RMATs.

The term “device” is defined in section 201(h) of the FD&C Act (21 U.S.C. 321) as:

an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, which is:

• recognized in the official National Formulary, or the United States Pharmacopoeia, or any supplement to them,
• intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or
• intended to affect the structure or any function of the body of man or other animals, and

which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes.

Under section 506(g) of the FD&C Act, a drug is eligible for RMAT designation if:

• it is a regenerative medicine therapy as defined in section 506(g)(8) of the FD&C Act (21. U.S.C. 356(g)(8));
• it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and
• preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition.

---

4 With respect to the RMAT designation program, all references to drugs or drug products refer to human drugs, including drugs that are biological products, unless otherwise specified. For further discussion of the RMAT designation program, please see the guidance document entitled “Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Guidance for Industry,” dated February 2019. As discussed in that guidance, a combination product (biologic-device, biologic-drug, or biologic-device-drug) can also be eligible for RMAT designation when the biological product constituent part is a regenerative medicine therapy and provides the greatest contribution to the overall intended therapeutic effects of the combination product (i.e., the primary mode of action of the combination product is conveyed by the biological product constituent part).

5 For information regarding FDA’s interpretation of “regenerative medicine therapy,” as defined in section 506(g)(8) of the FD&C Act, please see the guidance document entitled “Expedited Programs for Regenerative Medicine Therapies for Serious Conditions; Guidance for Industry,” dated February 2019.
Although section 3034 of the Cures Act refers to “recovery, isolation, or delivery,” these terms are not defined in the Cures Act. For the purpose of this guidance only,

- *recovery* means obtaining cells or tissues from a human donor;
- *isolation* is processing that results in selection, separation, enrichment, or depletion of recovered cells or tissues that will become components of the final product; and
- *delivery* refers to any method by which an RMAT is introduced onto or into the body of a human recipient, for example, infusion, injection, topical application, or inhalation.

Under Title 21 of the Code of Federal Regulations Part 3.2(e) (21 CFR 3.2(e)), *combination product* includes:

1) A product comprised of two or more regulated components, i.e., drug/device, biologic/device, drug/biologic, or drug/device/biologic, that are physically, chemically, or otherwise combined or mixed and produced as a single entity;
2) Two or more separate products packaged together in a single package or as a unit and comprised of drug and device products, device and biological products, or biological and drug products;
3) A drug, device, or biological product packaged separately that according to its investigational plan or proposed labeling is intended for use only with an approved individually specified drug, device, or biological product where both are required to achieve the intended use, indication, or effect and where upon approval of the proposed product the labeling of the approved product would need to be changed, e.g., to reflect a change in intended use, dosage form, strength, route of administration, or significant change in dose; or
4) Any investigational drug, device, or biological product packaged separately that according to its proposed labeling is for use only with another individually specified investigational drug, device, or biological product where both are required to achieve the intended use, indication, or effect.

FDA recognizes that a wide range of devices may be used in conjunction with an RMAT. For example, the devices can be simple, low risk devices, such as a manual surgical instrument (e.g., scalpel) for recovering cells and tissue. Devices used with RMATs may also be complex, higher risk devices, such as an automated cell collection system that selects and processes specific cells intended for immediate return back to the patient. Additionally, devices can be constituent parts of an RMAT that is a combination product.

The Agency does not consider device scaffolds combined with a cellular product to be within the scope of this guidance. While such constructs may be eligible for RMAT designation, the scaffold constituent part would generally be considered a part of the RMAT and would generally not be considered solely a “device used in the delivery of an RMAT” because such scaffolds provide more than a delivery function.

The use of general use equipment (e.g., centrifuges, cell washers, chromatography columns) in the manufacture of an RMAT outside of a direct patient care setting is reviewed under the Investigational New Drug Applications (IND)/Biologics License Applications (BLA) for the
RMAT. Therefore, this guidance does not address such equipment. In addition, medical devices that are not used in the recovery, isolation, or delivery of RMATs, such as in vitro diagnostics or companion diagnostics, are outside the scope of this guidance.

III. GENERAL APPROACH: DEVICE CLASSIFICATION AND STREAMLINING OF APPLICATION OF REGULATORY REQUIREMENTS

The appropriate regulatory evaluation pathway for devices that are not reviewed solely under a BLA as a constituent part of a biologic-led combination product and that are used in the recovery, isolation, or delivery of RMATs, and Center jurisdiction\(^6\) for such devices, may vary depending upon the devices’ technological characteristics and intended uses. The devices’ characteristics and intended uses are, in turn, generally based on the characteristics and conditions of use of the associated RMAT and the role of the device in the final product.

The classification of a device is a primary factor in determining the available premarket pathway for the device. The requirements for device classification are found in section 513 of the FD&C Act (21 U.S.C. 360c).

Section 513(a) of the FD&C Act (21 U.S.C. 360c(a)) establishes three classes of devices based on the regulatory controls needed to provide reasonable assurance of their safety and effectiveness: Class I (general controls), Class II (special controls in addition to general controls), and Class III (premarket approval in addition to general controls). Although a device’s intended uses and technological characteristics are considered during classification, FDA has no predetermined list of intended uses or specific attributes which would result in a device used with an RMAT (or any device) to be classified as a Class III device. Under section 513(a)(1)(C) of the FD&C Act, Class III devices are those that support or sustain human life, are of substantial importance in preventing impairment of human health, or which present a potential unreasonable risk of illness or injury, and for which there is insufficient information to determine that general and/or special controls would provide reasonable assurance of safety and effectiveness.\(^7\) Further, under section 513(f)(1) of the FD&C Act (21 U.S.C. 360c(f)(1)), postamendments devices (devices that were not in commercial distribution before May 28, 1976, the date the Medical Device Amendments were enacted) are statutorily classified in Class III unless FDA classifies or reclassifies them into Class I or II, or determines that such a device is “substantially equivalent”

---


\(^7\) Section 513(a)(1)(C) of the FD&C Act (21 U.S.C. 360c(a)(1)(C)).
(SE)\textsuperscript{8} to another device for which premarket approval is not required.\textsuperscript{9} Thus, a postamendments device may be subject to regulation as a Class I or II device in certain circumstances, including when:

- the device is within a type of device that has been classified into Class I or II and FDA has found the device to be SE to a device within such type;
- the device is within a type of preamendments device that is unclassified and FDA has found the device to be SE to a device within such type; or
- FDA has classified or reclassified the device type in Class I or II in accordance with sections 513(f)(2)\textsuperscript{10} or 513(f)(3) of the FD&C Act (21 U.S.C. 360c(f)(2), and (3)).

A. Least Burdensome Principles

FDA applies the level of regulation necessary to provide reasonable assurance that a medical device is safe and effective for its intended use. In accordance with the “least burdensome provisions” of the FD&C Act,\textsuperscript{11} the least burdensome principles apply to FDA requests for information related to (1) demonstrating a reasonable assurance of device safety and effectiveness in PMAs\textsuperscript{12} and (2) determinations of substantial equivalence for devices with technological characteristics that differ from those of the predicate device.\textsuperscript{13}

In conducting premarket review of a medical device, FDA requests information that is necessary to make a determination of whether the statutory standards for marketing authorization are met in accordance with the least burdensome principle. Based on the least burdensome principle, the term “necessary” means that FDA considers “the minimum required information that would support” (1) “a determination by [FDA] that an application provides reasonable assurance of the safety and effectiveness of the device”\textsuperscript{14} or (2) “a determination of substantial equivalence between a new device and a predicate device.”\textsuperscript{15}

\textsuperscript{8} Substantial equivalence is defined at section 513(i) of the FD&C Act (21 U.S.C. 360c(i)). FDA generally evaluates substantial equivalence on the basis of a premarket notification submitted pursuant to section 510(k) of the FD&C Act (21 U.S.C. 360(k)). Certain devices are subject to a statutory exemption from the 510(k) premarket notification requirement (see sections 510(l) and (m) of the FD&C Act (21 U.S.C. 360(l) and (m)).

\textsuperscript{9} A preamendments device for which premarket approval is not required could be a preamendments device that has been classified into Class I or Class II, a preamendments device that has been classified into Class III but for which a regulation under section 515(b) of the FD&C Act (21 U.S.C. 360e(b)) requiring the submission of an application for premarket approval (PMA) has not yet been issued, or a preamendments device that has not yet been classified.

\textsuperscript{10} This process is referred to as “De Novo” classification, and is described in more detail in section III.B.2. of this guidance.

\textsuperscript{11} The FDA Modernization Act of 1997 (FDAMA) added two provisions, commonly known as the “least burdensome provisions,” to the FD&C Act; related provisions were added to the statute by the FDA Safety and Innovation Act of 2012 (FDASIA) (Pub. L. 112-144) and the Cures Act.

\textsuperscript{12} Sections 513(a)(3)(D)(ii) and 515(c)(5) of the FD&C Act (21 U.S.C. 360c(a)(3)(D)(ii), 360e(c)(5)).

\textsuperscript{13} See section 513(i)(1)(D)(i) of the FD&C Act (21 U.S.C. 360c(i)(1)(D)(i)).

\textsuperscript{14} Section 515(c)(5) of the FD&C Act (21 U.S.C. 360e(c)(5)).

\textsuperscript{15} Section 513(i)(1)(D)(ii) of the FD&C Act (21 U.S.C. 360c(i)(1)(D)(ii)).
Contains Nonbinding Recommendations

Additional information related to how FDA intends to apply the least burdensome provisions is available in the following FDA guidances (“Least Burdensome Guidances”) that discuss the principles with which the recommendations discussed in this guidance are consistent:


B. Available Premarket Pathways

The appropriate premarket submission pathway for a given medical device is determined by the risks associated with the device type as well as the level of regulatory controls necessary to provide a reasonable assurance of safety and effectiveness. The available submission pathways (e.g., premarket notification (510(k)), De Novo classification (De Novo) request, Premarket Approval (PMA) Application, or Humanitarian Device Exemption (HDE)) are briefly discussed in sections III.B.1-4 of this guidance.

When clinical evidence is necessary to support marketing authorization of a medical device, an investigational device exemption (IDE) may be necessary. An IDE allows the investigational device to be used in a clinical study in the United States in order to collect safety and effectiveness data. An approved IDE permits a device to be shipped lawfully for the purpose of conducting investigations of the device. FDA has published numerous guidance documents related to IDEs, which can be found at: https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/InvestigationalDeviceExemptionIDE/ucm162453.htm.

Although a manufacturer or sponsor may submit any form of evidence to FDA in an attempt to substantiate the safety and effectiveness of a device, the Agency relies upon only valid scientific evidence to determine whether there is reasonable assurance that the device is safe and effective. After considering the nature of the device and the rules in 21 CFR 860.7, the Commissioner will determine whether the evidence submitted or

16 See Section 520(g) of the FD&C Act (21 U.S.C. 360j(g)) and 21 CFR 812.2.
17 Valid scientific evidence is defined as “evidence from well-controlled investigations, partially controlled studies, studies and objective trials without matched controls, well-documented case histories conducted by qualified experts, and reports of significant human experience with a marketed device, from which it can fairly and responsibly be concluded by qualified experts that there is reasonable assurance of the safety and effectiveness of a device under its conditions of use.” (21 CFR 860.7(c)(2)).
otherwise available to the Commissioner is valid scientific evidence for the purpose of
determining the safety or effectiveness of a particular device and whether the available
evidence, when taken as a whole, is adequate to support a determination that there is
reasonable assurance that the device is safe and effective for its conditions of use.18

1. Premarket Notification (510(k))

If FDA has previously cleared through a 510(k) or granted a De Novo request for
another device of the same type (i.e., a legally-marketed predicate device),19 as a new
device, a 510(k) is typically the appropriate pathway for the new device.20 Additional
information on the 510(k) Program can be found in the guidance document entitled
“The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications
[510(k)]; Guidance for Industry and Food and Drug Administration Staff,” dated July
28, 2014, available at https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-

2. De Novo Classification Request

Devices of a new type that FDA has not previously classified based on the criteria at
section 513(a)(1) of the FD&C Act (21 U.S.C. 360c(a)(1)) are ‘automatically’ or
‘statutorily’ classified into Class III.21 However, if the device appears, based on what
is known about the device, to meet the statutory standards for classification into Class
I or II under section 513(a)(1) of the FD&C Act, (i.e., general controls or general and
special controls would provide reasonable assurance of the safety and effectiveness
of the device), the device may be eligible for De Novo classification.22 If the requester
demonstrates that the device meets the statutory standards for classification into Class
I or II under section 513(a)(1) of the FD&C Act, i.e., that general controls, or a
combination of general controls and special controls, are sufficient to provide a
reasonable assurance of safety and effectiveness, FDA will grant the De Novo request
and issue a written order classifying the specific device and device type in Class I or
Class II.

Additional information on the De Novo Program can be found in the guidance
document entitled “De Novo Classification Process (Evaluation of Automatic Class
III Designation); Guidance for Industry and Food and Drug Administration Staff,”
danceDocuments/ucm080197.pdf.

18 21 CFR 860.7(c)(1).
19 Under 21 CFR 807.92(a)(3), a legally marketed predicate is a device that: (1) was legally marketed in the United
States prior to May 28, 1976 (preamendments device) and for which a PMA is not required; or (2) has been
reclassified from Class III to II or I; or (iii) has been found substantially equivalent (SE) though the 510(k) process.
20 See section 510(k) of the FD&C Act (21 U.S.C. 360(k)), and 21 CFR Part 807 Subpart E.
21 Section 513(f)(1) of the FD&C Act (21 U.S.C. 360c(f)(1)).
22 FDA may decline to undertake a De Novo request if the conditions set forth in section 513(f)(2)(A)(iv) of the
3. Premarket Approval Application

Premarket approval (PMA) is required before most Class III devices can be marketed.23 A PMA application must demonstrate a “reasonable assurance of safety and effectiveness” by “weighing any probable benefit to health from the use of the device against any probable risk of injury or illness from such use,” among other relevant factors.24 To aid in this process, PMA applicants submit valid scientific evidence, including one or more clinical investigations where appropriate, which FDA reviews to determine whether “the device will have the effect it purports or is represented to have under the conditions of use prescribed, recommended, or suggested in the labeling of the device.”25


4. Humanitarian Device Exemption (HDE)

An HDE provides a regulatory path for devices that are intended to benefit patients with rare diseases or conditions. To be eligible for an HDE, a device must first be designated as a Humanitarian Use Device (HUD).26 Additional information about the HUD designation process can be found in the draft guidance document entitled “Humanitarian Device Exemption (HDE) Program; Draft Guidance for Industry and Food and Drug Administration Staff,” dated June 13, 2018,27 available at https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm389275.pdf.

FDA understands that applicants may have questions prior to submitting a premarket application. We have established a structured process for managing the various types of requests for feedback prior to a premarket submission, referred to as “Q-Submissions.” FDA has issued guidance that provides an overview of the mechanisms available to

---

23 See section 513(a)(1)(C) of the FD&C Act (21 U.S.C. 360c(a)(1)(C)).
24 See sections 513(a)(2), 515(d)(1)(A), and 515(d)(2)(A)-(B) of the FD&C Act (21 U.S.C. 360c(a)(2), 360e(d)(1)(A) and (d)(2)(A)-(B)); see also 21 CFR 860.7(b), (d), and (e).
26 21 CFR 814.102(a).
27 When finalized, this guidance will represent FDA’s current thinking on this topic.
applicants through which they can request feedback from FDA regarding potential or planned medical device IDE applications or other premarket submissions, such as PMA applications, HDE applications, De Novo requests, 510(k)s, and BLAs.\textsuperscript{28}

IV. COMBINATION PRODUCTS

Consistent with section 503(g)(1)(B) of the FD&C Act, added by the Cures Act, and the Agency’s approach to simplifying and streamlining the regulatory requirements for combination products in general, single entity combination products are generally reviewed under a single application.\textsuperscript{29} Devices intended for use with a specific RMAT may, together with the RMAT, be considered to comprise a biologic-led combination product and be evaluated for marketing under a BLA in the Center for Biologics Evaluation and Research (CBER), with consulting review by other center(s) as appropriate.\textsuperscript{30}

Some devices that can be used with approved RMATs may be evaluated independently using premarket submissions pathways identified in section III.B of this guidance. Examples may include some devices used in recovery (e.g., surgical tools, syringes, apheresis collection devices), or delivery (e.g., syringe, catheter). When a separate premarket application for a device to be used with an RMAT is appropriate, FDA will apply the least burdensome provisions of the FD&C Act as noted above to determine the “minimum required information” necessary for marketing authorization of that device.

In some instances, the device constituent part of an RMAT that is a combination product may be separately packaged. Separate marketing applications for each product may be appropriate, particularly, for example, if the delivery device may ultimately be labeled for use with multiple RMATs that have similar characteristics and administration requirements. In instances where there are separate applications for the RMAT(s) and device(s), fulfillment of regulatory requirements may be simplified or streamlined to reduce or avoid redundancy. For example, when appropriate and legally permissible, clinical or performance data generated in association with studies of one product may be submitted to support certain aspects of the approval or clearance of other, related product applications. It may also be possible for one regulatory submission to cross-reference existing performance data in another regulatory submission when available and when such reference is permissible. FDA intends to apply the least burdensome concept and principles in the guidance entitled, “The Least Burdensome Provisions: Concept and Principles; Guidance for Industry and Food and Drug Administration Staff,” dated


\textsuperscript{29} Section 503(g)(1)(B) of the FD&C Act (21 U.S.C. 353(g)(1)(B)) provides that FDA shall review combination products in a single application, whenever appropriate. Note that under section 503(g)(6) of the FD&C Act, also added by the Cures Act, a sponsor may choose to submit separate applications for the constituent parts of a combination product, unless FDA determines that a single application is necessary.

February 5, 2019,\textsuperscript{31} in determining the data and information necessary to support marketing authorization for the device for its intended use. FDA intends to apply these least burdensome concept and principles in the manner described regardless of how the device is presented for review, e.g., under a standalone application for more general use; or a constituent part, reviewed under a separate device application, of an RMAT that is a combination product; or under a single application for a combination product as a whole.

V. FACTORS TO CONSIDER FOR WHEN A DEVICE MAY BE INTENDED FOR USE WITH ONLY ONE PARTICULAR TYPE OF CELL-BASED RMAT OR WITH MORE THAN ONE TYPE OF CELL-BASED RMAT

RMAT designation is granted for a specific therapeutic product and specific intended uses. RMATs may represent a highly diverse group of products with distinct biological and physical characteristics. These characteristics, along with other factors such as target patient population (e.g., adult vs pediatric), intended use and conditions for use must be considered when determining which device, or devices, may be suitable for use with a specified RMAT or type of RMAT. These same factors will influence when a device may be limited to a specific intended use with only one particular cell-based RMAT or type of cell-based RMAT.

RMATs are likely to differ with regard to characteristics that can impact the way they interact with different devices, which may affect the RMAT’s safety and effectiveness. In the case of cellular products that are RMATs, including cellular products that are constituent parts of combination products, the interaction between cells and a device can have an impact on critical characteristics, such as cell viability, differentiation potential, activation state and ability to respond to stimuli after administration. Further, differences in physical characteristics such as cell size and sensitivity to shearing forces can directly impact the potential utility of a given device with a specific RMAT or type of RMAT. For example, it may not be possible to use a small bore catheter or pen/jet injector to deliver an RMAT that contains a large delicate cell type because the shearing forces may negatively impact cell viability. In contrast, an RMAT that contains a smaller, more robust cell type may require the use of a small bore catheter to facilitate delivery to a specific tissue site, but have special requirements to prevent the cells from adsorbing to the interior catheter surface or to each other, resulting in occlusion of the tip. Such factors along with the demonstrated performance will influence whether the device can obtain marketing authorization for a broader use or should be limited to use with a specific RMAT(s).

Because cellular products can possess extremely variable sensitivities to physical and chemical stimuli, it may be necessary to repeat testing to assess interactions of each new device-RMAT combination. To leverage compatibility data for a different device-RMAT combination, a detailed and specific scientific rationale for the applicability of this data would be needed. Sufficient compatibility data should be provided to the Agency prior to initiation of clinical trials.

\textsuperscript{31} The draft guidance is available at: https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM085999.pdf
During development, a given RMAT may be determined to have characteristics and use requirements that would allow it to be administered using a general class of devices (e.g., conventional syringe or catheter) or a specific subset of delivery device(s) with defined characteristics when such devices are used as labeled. Experience gained over time with a specific RMAT or class of RMATs in different use settings may also allow for identification of a general class or subset of delivery devices. If there is sufficient evidence that the safety and effectiveness of the RMAT would not be compromised when administered with the identified general class or specific subset of delivery devices, the RMAT could be approved with more general labeling rather than specifying a particular delivery device. In such cases, the labeling of the RMAT would specify the defined characteristics of the general class of devices (e.g., conventional syringe or catheter) or specific subset of delivery device(s) with which it is intended to be administered.